scholarly journals User Experience and Potential Health Effects of a Conversational Agent-Based Electronic Health Intervention: Protocol for an Observational Cohort Study

10.2196/16641 ◽  
2020 ◽  
Vol 9 (4) ◽  
pp. e16641
Author(s):  
Marian Z M Hurmuz ◽  
Stephanie M Jansen-Kosterink ◽  
Harm op den Akker ◽  
Hermie J Hermens

Background While the average human life expectancy has increased remarkably, the length of life with chronic conditions has also increased. To limit the occurrence of chronic conditions and comorbidities, it is important to adopt a healthy lifestyle. Within the European project “Council of Coaches,” a personalized coaching platform was developed that supports developing and maintaining a healthy lifestyle. Objective The primary aim of this study is to assess the user experience with and the use and potential health effects of a fully working Council of Coaches system implemented in a real-world setting among the target population, specifically older adults or adults with type 2 diabetes mellitus or chronic pain. Methods An observational cohort study with a pretest-posttest design will be conducted. The study population will be a dynamic cohort consisting of older adults, aged ≥55 years, as well as adults aged ≥18 years with type 2 diabetes mellitus or chronic pain. Each participant will interact in a fully automated manner with Council of Coaches for 5 to 9 weeks. The primary outcomes are user experience, use of the program, and potential effects (health-related factors). Secondary outcomes include demographics, applicability of the virtual coaches, and user interaction with the virtual coaches. Results Recruitment started in December 2019 and is conducted through mass mailing, snowball sampling, and advertisements in newspapers and social media. This study is expected to conclude in August 2020. Conclusions The results of this study will either confirm or reject the hypothesis that a group of virtual embodied conversational coaches can keep users engaged over several weeks of interaction and contribute to positive health outcomes. Trial Registration The Netherlands Trial Register: NL7911; https://www.trialregister.nl/trial/7911 International Registered Report Identifier (IRRID) PRR1-10.2196/16641


2020 ◽  
pp. 10-11
Author(s):  
Ravindra Kumar Das ◽  
Rahul Kumar Sinha ◽  
Debarshi Jana

Background: Type 2 diabetes mellitus (DM) is a progressive chronic disorder and sustained control of plasma glucose is essential to prevent complications. Pioglitazoneofthiazolidinedionesand sitagliptin of Dipeptidyl peptidase-4 inhibitors (DPP4I) have recently been used as add-on therapy to control type 2 DM. The aim of this study was to compare the plasma glucose and glycocelatedHb% level of both the group who had poor glycemic control with Metformin and sulfonylurea. MATERIAL AND METHODS: In this observational cohort study, 100 patients with uncontrolled type 2 DM on 2000 mg/day of Metformin and 4 mg/day of Glimepiride were enrolled. The patients were randomly allocated into two groups with fifty each. One group received two divided doses of pioglitazone (30 mg/day) and the other received two divided doses of sitagliptin (100 mg/day) as the third medication. Plasma glucose fasting and 2 hours after drug and meal along with HbA1c were assessed before and after three months of treatment. Results: Fasting plasma glucose level in the sitagliptin group was higher than the pioglitazone group; however, this difference was not statistically significant (130.30 ± 30.29 versus 124.58 ± 46.84, p=0.212). Significantdifferences were not observed in HbA1c (7.20±0.96 versus 7.43±0.99, p=0.563) and plasma glucose 2 hours after meal (194.56±66.22 versus 198.58±51.5, p=0.946) after treatment withsitagliptin and pioglitazone among the two groups. Mean weight in the sitagliptin group was lower compared to the pioglitazone group after treatment, however, this difference was not statistically significant (p=0.824). Conclusion: Both the molecule as third agent had similar efficacy in glycemic control. Sitagliptin is better choice to add-on therapy in obese overweight patients.





2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
H Op den Akker ◽  
M Hurmuz ◽  
S M Jansen-Kosterink

Abstract Background Due to the aging population, more and more older adults are living with chronic conditions. Adopting a healthy lifestyle can reduce the impact of these conditions. To address this issue, Council of Coaches (COUCH) has been developed within the Council of Coaches project (European Union's Horizon 2020 research and innovation program under grant agreement No. 769553). COUCH is a web application (TRL6), in which users can have virtual conversations with a group of embodied virtual coaches. These coaches give users information, feedback and tips on adopting a healthy lifestyle primarily in the areas of physical activity and nutrition. The aim of this evaluation is to assess the use, user experience, and potential health effects. Methods Use will be assessed by the log data of COUCH, and user experience and potential health effects will be assessed by questionnaires. The target population (older adults, 55 years or older) will participate in an observational cohort study with a pre-test/post-test design. Subjects will complete multiple questionnaires: before the baseline phase, after the implementation phase and, after the follow-up phase. Each participant will sign an informed consent form. Results The COUCH evaluation consists of two rounds. The first round started in February 2020, the second round will start in May 2020, with 25 subjects planned in each round. For the first round, 26 subjects are already recruited and included. For the second round, 12 subjects are already recruited. In August 2020, the results of the evaluation will be available. During this presentation, these results will be presented. This will consist of user demographics, use, user experience, and of the results on potential health effect. Conclusions This evaluation will give us a broad overview of the use, user experience and effectiveness of COUCH in a real-life setting, leading to further development of COUCH.



Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 131-OR
Author(s):  
VASILEIOS LIAKOPOULOS ◽  
ANN-MARIE SVENSSON ◽  
INGMAR NASLUND ◽  
BJORN ELIASSON


Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1975-P
Author(s):  
GUDRUN HÖSKULDSDOTTIR ◽  
NAVEED SATTAR ◽  
MERVETE MIFTARAJ ◽  
INGMAR NASLUND ◽  
JOHAN R. OTTOSSON ◽  
...  




Sign in / Sign up

Export Citation Format

Share Document